Acipimox


Generic Medicine Info
Indications and Dosage
Oral
Fredrickson type IIb hyperlipoproteinaemia, Fredrickson type IV hyperlipoproteinaemia
Adult: As an alternative or adjunct in patients who have not responded adequately to other treatments (e.g. statins, fibrates): Usual dose: 250 mg bid or tid. Dose is individualised based on the patient's plasma triglyceride and cholesterol levels. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Renal Impairment
Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).

CrCl (mL/min) Dosage
<30 Contraindicated.
30-60 250 mg once daily or bid.
Administration
Should be taken with food. Take w/ or after meals.
Contraindications
Active peptic ulcer. Severe renal impairment (CrCl <30 mL/min). Pregnancy and lactation. Contraindications may vary among individual products (refer to specific product labelling for detailed information).
Special Precautions
Patient with acute haemorrhage; heart failure. Management with dietary changes and other non-pharmacological treatments (e.g. exercise, weight reduction, smoking or alcohol cessation) should be attempted prior to initiating treatment. Hepatic and mild to moderate renal impairment.
Adverse Reactions
Significant: Pruritus, flushing, erythema, rash.
Eye disorders: Eye irritation, dry eyes.
Gastrointestinal disorders: Dyspepsia, upper abdominal pain, nausea, diarrhoea.
General disorders and administration site conditions: Asthenia, malaise, feeling hot.
Immune system disorders: Anaphylactoid reaction.
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, myositis.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Bronchospasm.
Skin and subcutaneous tissue disorders: Urticaria, angioedema.
Vascular disorders: Vasodilation.
Monitoring Parameters
Monitor lipid profile, liver and kidney function at baseline and periodically during therapy.
Drug Interactions
May enhance the myopathic (rhabdomyolysis) effect of statins and fibrates.
Action
Description: Acipimox lowers blood cholesterol by inhibiting the release of fatty acids from adipose tissue and reducing serum levels of VLDL and LDL with a subsequent overall lowering of triglyceride and cholesterol levels. Additionally, it increases HDL concentrations during treatment.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 2 hours.
Metabolism: Not significantly metabolised.
Excretion: Via urine (mainly unchanged). Elimination half-life: Approx 2 hours.
Chemical Structure

Chemical Structure Image
Acipimox

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5310993, Acipimox. https://pubchem.ncbi.nlm.nih.gov/compound/Acipimox. Accessed May 26, 2022.

Storage
Store below 30°C. Protect from moisture.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AD06 - acipimox ; Belongs to the class of nicotinic acid and derivatives. Used in the treatment of hyperlipidemia.
References
Anon. Acipimox. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/01/2022.

Buckingham R (ed). Acipimox. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/01/2022.

Joint Formulary Committee. Acipimox. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/01/2022.

Olbetam 250 mg Capsules (Pfizer Limited). MHRA. https://products.mhra.gov.uk. Accessed 13/01/2022.

Pfizer New Zealand Limited. Olbetam 250 mg Capsule data sheet 3rd May 2019. Medsafe. http://www.medsafe.govt.nz. Accessed 13/01/2022.

Disclaimer: This information is independently developed by MIMS based on Acipimox from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in